Peter Lawson

Yanan Zhu

Andrea Newkirk

Asthika Goonewardene

Colleen Kusy

David Dai

Reni Benjamin

Salim Syed

Tyler Van Buren

Andrew Tsai

Benjamin Burnett

Lin Tsai

Michael Yee

Nick Lorusso

- Iovance Biotherapeutics, Inc. released an updated corporate presentation on **August 29, 2025**, providing key financial and pipeline updates.  **[1425205_0001104659-25-085650_tm2524604d1_8k.htm:1]** 
- The company reported a cash position of **$307.1 million** as of **June 30, 2025**, with a projected cash runway into **Q4 2026** and an anticipated cash burn of less than **$245 million** from Q3 2025 to Q3 2026.  **[1425205_0001104659-25-085650_tm2524604d1_ex99-1.htm:3]**  
- Iovance provided FY 2025 revenue guidance of **$250 million** to **$300 million** and announced a strategic restructuring expected to yield over **$100 million** in annual cost savings starting in Q4 2025.   
- The company highlighted its commercial products, **Amtagvi** and **Proleukin**, which generated over **$240 million** in product revenue for the 12 months ending June 30, 2025, and provided updates on its clinical pipeline, including the Phase 3 TILVANCE-301 trial for frontline advanced melanoma.  **[1425205_0001104659-25-085650_tm2524604d1_ex99-1.htm:3]** **[1425205_0001104659-25-085650_tm2524604d1_ex99-1.htm:6]** **[1425205_0001104659-25-085650_tm2524604d1_ex99-1.htm:7]**

IOVANCE BIOTHERAPEUTICS, INC. Updates Corporate Presentation with Financial Guidance and Pipeline Progress

IOVANCE BIOTHERAPEUTICS (IOVA)